Vaxcyte (PCVX) Non Operating Income (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Non Operating Income data on file, last reported at $25.2 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $25.2 million, down 37.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $142.2 million (up 12.64% YoY), and the FY2025 annual result was $157.0 million, up 48.69% from the prior year.
• Non Operating Income eased to $25.2 million in Q1 2026 per PCVX's latest filing, from $27.8 million in the prior quarter.
• Over five years, Non Operating Income peaked at $59.6 million in Q2 2025 and troughed at -$646000.0 in Q2 2022.
• A 5-year average of $21.3 million and a median of $20.4 million in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income sank 1366.67% in 2022, then jumped 4465.96% in 2023.
• A 5-year view of Non Operating Income shows it stood at $8.5 million in 2022, then soared by 86.26% to $15.9 million in 2023, then soared by 58.04% to $25.1 million in 2024, then gained by 10.71% to $27.8 million in 2025, then dropped by 9.17% to $25.2 million in 2026.
• Business Quant data shows PCVX's Non Operating Income at $25.2 million in Q1 2026, $27.8 million in Q4 2025, and $29.6 million in Q3 2025.